Oramed will release its PhII data for insulin pill this week; Medac Pharma submits NDA for arthritis injection;

> Medac Pharma had its NDA accepted by the FDA for a subcutaneous injectable methotrexate and injection device for arthritis. More

> Oramed is set to announce the results of a Phase IIa trial for oral insulin this week. Release

> 3-D Matrix filed a patent infringement complaint against Menicon and B-Bridge International for its self-assembling peptide technology. Release

> Researchers in Iran published a study in the journal RSC Advances that shows the utility of a biodegradable heparin-coated nanocomposite system for targeted drug delivery to tumors. Abstract

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.